MedTrace Logo

Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance

NCT03470337 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-03-19

No results posted yet for this study

Summary

Oral enzyme therapy in patients with acute superficial vein inflammation (thrombophlebitis) can serve as an additional treatment option besides standard therapy with compression stockings, common pain medication and physical treatments. This randomized, double-blinded trial compares efficacy and safety with placebo.

Conditions

  • Thrombophlebitis Leg

Interventions

DRUG

Phlogenzym

Bromelain / Trypsin / Rutoside

OTHER

Placebo

Sponsors & Collaborators

  • Mucos Pharma GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Marcel Baumueller, MD · Private Practice

  • Gerhard Stauder, Dr · Mucos Pharma GmbH & Co. KG (EX)

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-09-30
Primary Completion
1997-06-30
Completion
1997-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03470337 on ClinicalTrials.gov